Pharmaids Pharma

Why is Pharmaids Pharmaceuticals Ltd falling/rising?

As of 11-Aug, Pharmaids Pharmaceuticals Ltd's stock price is at Rs 34.00, reflecting a 2.94% decline. The stock has shown a negative trend with a year-to-date drop of 28.66%, underperforming its sector and indicating a longer-term bearish outlook.

As of 11-Aug, Pharmaids Pharmaceuticals Ltd's stock price is falling, currently at Rs 34.00, which reflects a decrease of Rs 1.03 or 2.94%. This decline is evident in today's performance, where the stock underperformed its sector by 3.77%. Throughout the day, the stock experienced a wide trading range, reaching a high of Rs 36.3 but also dipping to a low of Rs 32.99, indicating significant volatility.<BR><BR>In terms of recent performance, the stock has shown a negative trend over various periods, with a year-to-date decline of 28.66% and a one-year drop of 45.62%. This is in stark contrast to the benchmark Sensex, which has only decreased by 8.29% over the same year-to-date period. Additionally, investor participation appears to be waning, as evidenced by a 7.45% drop in delivery volume compared to the five-day average.<BR><BR>Despite the stock trading above its shorter-term moving averages (5-day, 20-day, 50-day, and 100-day), it remains below the 200-day moving average, suggesting a longer-term bearish trend. Overall, these factors contribute to the current decline in Pharmaids Pharmaceuticals Ltd's stock price.

Which are the latest news on Pharmaids Pharma?

When is the next results date for Pharmaids Pharmaceuticals Ltd?

The next results date for Pharmaids Pharmaceuticals Ltd is 12 August 2026.

The next results date for Pharmaids Pharmaceuticals Ltd is scheduled for 12 August 2026.

What does Pharmaids Pharma do?

Pharmaids Pharmaceuticals Ltd provides contract research and manufacturing services in the Pharmaceuticals & Biotechnology sector. As of March 2026, it reported net sales of 7 Cr and a net loss of 2 Cr, with a market cap of INR 96 Cr.

Overview:<BR>Pharmaids Pharmaceuticals Ltd is engaged in contract research and manufacturing services within the Pharmaceuticals & Biotechnology industry and operates as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in March 1989 in Hyderabad, Telangana. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 96 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.49 <BR>Return on Equity: -29.75% <BR>Price to Book: 2.11<BR><BR>Contact Details:<BR>Address: 4-4-211/212/3 1st Floor, Inderbagh Sulthan Bazar Hyderabad Telangana : 500095 <BR>Tel: 91-40-66669809 <BR>Email: mailpharmaids@yahoo.co.in <BR>Website: http://www.pharmaids.com

How big is Pharmaids Pharma?

As of 10th June, Pharmaids Pharmaceuticals Ltd has a market capitalization of 96.00 Cr and reported Net Sales of 27.88 Cr with a Net Profit loss of 11.72 Cr over the latest four quarters. The balance sheet for March 2025 shows Shareholder's Funds of 59.32 Cr and Total Assets of 109.35 Cr.

As of 10th June, Pharmaids Pharmaceuticals Ltd has a market capitalization of 96.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 27.88 Cr. However, it experienced a loss of 11.72 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 59.32 Cr and Total Assets of 109.35 Cr.

Who are in the management team of Pharmaids Pharma?

The management team of Pharmaids Pharma includes Venu Madhava Kaparthy and Mini Manikantan as Executive Directors, along with Sadhanala Venkata Rao, P N Vijay, M Sudheer Anand, Methuku Nagesh as Independent Non-Executive Directors, and Shreedhara Shetty as an Additional Director. They are responsible for the company's governance and strategic direction.

The management team of Pharmaids Pharma includes the following individuals:<BR><BR>1. **Venu Madhava Kaparthy** - Executive Director & Wholetime Director<BR>2. **Mini Manikantan** - Executive Director & Wholetime Director<BR>3. **Sadhanala Venkata Rao** - Non-Executive & Non-Independent Director<BR>4. **P N Vijay** - Independent Non-Executive Director<BR>5. **M Sudheer Anand** - Independent Non-Executive Director<BR>6. **Methuku Nagesh** - Independent Non-Executive Director<BR>7. **Shreedhara Shetty** - Additional Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

Who are the peers of the Pharmaids Pharma?

Pharmaids Pharma's peers include Tyche Industries, Godavari Drugs, and several others. It has below-average management and growth ratings, with a 1-year return of -52.99%, significantly lower than its peers.

Peers: The peers of Pharmaids Pharma are Tyche Industries, Godavari Drugs, Concord Drugs, Denis Chem Lab, Mercury Labs, Amwill Health, Makers Labs, Vaishali Pharma, and Sotac Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Denis Chem Lab and Amwill Health, while Average management risk is found at Tyche Industries, Mercury Labs, and the rest. Below Average management risk is seen at Concord Drugs, Pharmaids Pharma, Makers Labs, Vaishali Pharma, and Sotac Pharma. Growth ratings show that Excellent growth is at Amwill Health, while Average growth is at Tyche Industries, Mercury Labs, and the rest. Below Average growth is noted at Godavari Drugs, Concord Drugs, Pharmaids Pharma, Makers Labs, and Vaishali Pharma. Capital Structure ratings indicate Excellent capital structure at Tyche Industries and Denis Chem Lab, while Average capital structure is found at Sotac Pharma, and Below Average capital structure is seen at Godavari Drugs, Concord Drugs, Pharmaids Pharma, Mercury Labs, Makers Labs, and Vaishali Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Godavari Drugs at 24.25%, while Pharmaids Pharma has the lowest at -52.99%. This indicates that Pharmaids Pharma's 1-year return is significantly worse than its peers. Additionally, the six-month return is negative for Pharmaids Pharma, Denis Chem Lab, Mercury Labs, Amwill Health, and Makers Labs.

Should I buy, sell or hold Pharmaids Pharmaceuticals Ltd?

Are Pharmaids Pharmaceuticals Ltd latest results good or bad?

Pharmaids Pharmaceuticals Ltd's latest results are largely negative, showing a net loss of ₹1.81 crores despite a 50.52% revenue growth. While there are slight improvements in operating margins, persistent losses and a significant stock decline raise concerns about the company's financial health.

Pharmaids Pharmaceuticals Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. In Q4 FY26, the company reported a net loss of ₹1.81 crores, which is a decrease of 27.02% quarter-over-quarter and 54.06% year-over-year. While revenue showed a significant year-on-year growth of 50.52%, reaching ₹7.18 crores, this topline growth has not translated into profitability.<BR><BR>The operating margin improved from -46.04% in the previous quarter to -4.74%, indicating some operational progress, but the company remains in loss-making territory. The profit after tax margin was also concerning at -15.04%. <BR><BR>Additionally, the stock has underperformed significantly, declining 55.48% over the past year, which raises investor concerns about its sustainability and ability to achieve profitability. The company's financial metrics, including a negative return on equity of -29.75% and a high employee cost ratio, further highlight ongoing operational inefficiencies.<BR><BR>In summary, while there are some signs of improvement in revenue and margins, the persistent losses and overall financial health suggest that the latest results are more bad than good. Investors should be cautious given the company's ongoing challenges.

How has been the historical performance of Pharmaids Pharma?

Pharmaids Pharma has seen net sales grow to 19.45 Cr in March 2025 from 0.00 Cr in March 2023, but continues to report significant losses, with an operating profit of -12.66 Cr and a profit after tax of -13.51 Cr in March 2025, alongside rising total assets and liabilities. Cash flow from operating activities remains negative at -13.00 Cr, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Pharmaids Pharma shows a gradual increase in net sales, reaching 19.45 Cr in March 2025, up from 15.11 Cr in March 2024 and starting from 0.00 Cr in March 2023. However, the company has consistently reported negative operating profits, with an operating profit of -12.66 Cr in March 2025, slightly worse than -12.33 Cr in March 2024 and -9.88 Cr in March 2023. The total expenditure has risen to 32.21 Cr in March 2025 from 28.32 Cr in March 2024, contributing to a profit before tax of -17.28 Cr in March 2025, compared to -15.62 Cr in March 2024 and -9.91 Cr in March 2023. The profit after tax also reflects this trend, with losses of -13.51 Cr in March 2025, -11.84 Cr in March 2024, and -7.56 Cr in March 2023. The company's total assets increased to 109.35 Cr in March 2025 from 84.67 Cr in March 2024, while total liabilities also rose to 109.35 Cr from 84.67 Cr, indicating a growing financial burden. Cash flow from operating activities remained negative at -13.00 Cr in March 2025, worsening from -10.00 Cr in March 2024.<BR><BR>Breakdown:<BR>Pharmaids Pharma has demonstrated a notable increase in net sales over the past three years, achieving 19.45 Cr in March 2025, which marks a significant rise from 15.11 Cr in March 2024 and an initial 0.00 Cr in March 2023. Despite this growth in revenue, the company has faced persistent challenges with profitability, as evidenced by its operating profit margins remaining deeply negative, culminating in an operating profit of -12.66 Cr in March 2025. The total expenditure has also escalated, leading to a profit before tax of -17.28 Cr in March 2025, reflecting a deterioration in financial performance compared to previous years. The company's total assets and liabilities have both increased, reaching 109.35 Cr in March 2025, indicating a rise in financial obligations. Furthermore, the cash flow from operating activities has remained negative, highlighting ongoing operational difficulties. Overall, while Pharmaids Pharma has shown growth in sales, it continues to struggle with significant losses and rising costs.

Who are the top shareholders of the Pharmaids Pharma?

The top shareholders of Pharmaids Pharma include promoter Sadhanala Venkata Rao with 4.4% and public shareholder Shankarappa Nagaraja Vinaya Babu with 19.91%. Individual investors collectively hold 36.59%, with no institutional holdings reported.

The top shareholders of Pharmaids Pharma include Sadhanala Venkata Rao, who is the promoter with the highest holding at 4.4%. Additionally, the highest public shareholder is Shankarappa Nagaraja Vinaya Babu, holding 19.91%. Individual investors collectively hold 36.59% of the shares. It's worth noting that there are no institutional holdings from mutual funds or foreign institutional investors.

Is Pharmaids Pharma overvalued or undervalued?

As of July 26, 2023, Pharmaids Pharma is considered a risky investment due to its negative PE ratio of -19.15, unfavorable valuation metrics compared to peers like Sun Pharma and Cipla, and a year-to-date stock performance of -17.99%, indicating it may be overvalued at its current price of 57.80.

As of 26 July 2023, Pharmaids Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued, especially when considering its negative PE ratio of -19.15, an EV to EBITDA of -18.92, and a ROE of -18.00%. These figures suggest that the company is struggling to generate profits relative to its valuation metrics.<BR><BR>In comparison to its peers, Pharmaids Pharma's valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla, which is rated attractive, has a PE of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights Pharmaids Pharma's challenges in the market. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -17.99% compared to the Sensex's 5.62%, reinforcing the notion that it may be overvalued at its current price of 57.80.

What is the technical trend for Pharmaids Pharma?

As of June 2, 2025, Pharmaids Pharma's technical trend is mildly bearish, indicated by bearish MACD and KST signals on both weekly and monthly timeframes, despite some mixed signals from Bollinger Bands and mildly bullish daily moving averages.

As of 2 June 2025, the technical trend for Pharmaids Pharma has changed from sideways to mildly bearish. The weekly MACD and KST indicators are both mildly bearish, while the monthly MACD and KST also reflect a bearish stance. The RSI shows no signal on the weekly timeframe but is bearish on the monthly, indicating weakness. Bollinger Bands present a bearish signal on the weekly and mildly bullish on the monthly, suggesting mixed signals. Moving averages on the daily timeframe are mildly bullish, which contrasts with the overall bearish sentiment. Dow Theory confirms a mildly bearish stance on both weekly and monthly timeframes. Overall, the technical stance is mildly bearish, driven primarily by the MACD, KST, and Dow Theory indicators.

Has Pharmaids Pharma declared dividend?

No Dividend History Available